发文分析
近年国家/地区发文量统计
| 国家/地区 | 数量 |
|---|---|
| USA | 189 |
| England | 74 |
| Italy | 67 |
| France | 61 |
| Netherlands | 49 |
| GERMANY (FED REP GER) | 42 |
| Spain | 38 |
| Canada | 36 |
| Australia | 29 |
| Japan | 24 |
近年机构发文量统计
| 机构 | 数量 |
|---|---|
| ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP) | 38 |
| UNIVERSITY OF LONDON | 33 |
| UNIVERSITY OF TEXAS SYSTEM | 33 |
| HARVARD UNIVERSITY | 31 |
| UNIVERSITE DE PARIS | 26 |
| DANA-FARBER CANCER INSTITUTE | 24 |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC... | 20 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 19 |
| UNICANCER | 19 |
| UNIVERSITY OF AMSTERDAM | 19 |
近年文章引用他刊数据
| 文章名称 | 引用次数 |
|---|---|
| A clinical prediction model for cancer-associated venous... | 53 |
| Ruxolitinib in adult patients with secondary haemophagoc... | 50 |
| A combination of humanised anti-CD19 and anti-BCMA CAR T... | 44 |
| Pembrolizumab plus pomalidomide and dexamethasone for pa... | 43 |
| Efficacy, safety, and pharmacokinetics of emicizumab pro... | 43 |
| Safety and activity of ibrutinib in combination with niv... | 41 |
| Haematological immune-related adverse events induced by ... | 41 |
| Momelotinib versus best available therapy in patients wi... | 39 |
| Polatuzumab vedotin or pinatuzumab vedotin plus rituxima... | 38 |
| Pembrolizumab plus lenalidomide and dexamethasone for pa... | 38 |
近年被他刊引用数据
| 期刊名称 | 引用次数 |
|---|---|
| LANCET HAEMATOL | 86 |
| BRIT J HAEMATOL | 62 |
| BLOOD ADV | 59 |
| BLOOD | 57 |
| HAEMATOLOGICA | 54 |
| LEUKEMIA LYMPHOMA | 50 |
| BIOL BLOOD MARROW TR | 43 |
| CL LYMPH MYELOM LEUK | 39 |
| EXPERT REV HEMATOL | 36 |
| CANCERS | 34 |